Scientists test new imaging tracer to see inside the immune System's fight against cancer
NCT ID NCT05259709
Summary
This early-stage study is testing a new imaging agent, 89Zr-DFO-REGN5054, in patients with advanced solid tumors who are receiving the immunotherapy drug cemiplimab. The main goal is to see if the imaging agent is safe and to understand how it moves through the body. Researchers hope this tracer can help them see and measure specific immune cells (CD8+ T cells) inside tumors using PET scans, which could improve understanding of how immunotherapy works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UMC Groningen
RECRUITINGGroningen, 9700 RB, Netherlands
Conditions
Explore the condition pages connected to this study.